Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force

S. Gauthier; J. Alam; H. Fillit; T. Iwatsubo; H. Liu-Seifert; M. Sabbagh; S. Salloway; C. Sampaio; J. R. Sims; B. Sperling; R. Sperling; K. A. Welsh-Bohmer; J. Touchon; B. Vellas; P. Aisen

doi:10.14283/jpad.2019.12

Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force

S. Gauthier, J. Alam, H. Fillit, T. Iwatsubo, H. Liu-Seifert, M. Sabbagh, S. Salloway, C. Sampaio, J. R. Sims, B. Sperling, R. Sperling, K. A. Welsh-Bohmer, J. Touchon, B. Vellas, P. Aisen

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Combination therapy is expected to play an important role for the treatment of Alzheimer's disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer's Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.

Original language	English
Pages (from-to)	164-168
Number of pages	5
Journal	The journal of prevention of Alzheimer's disease
Volume	6
Issue number	3
DOIs	https://doi.org/10.14283/jpad.2019.12
State	Published - 2019

Keywords

Alzheimer’s disease
amyloid
tau
therapeutics
trial design

Access to Document

10.14283/jpad.2019.12

Cite this

Gauthier, S., Alam, J., Fillit, H., Iwatsubo, T., Liu-Seifert, H., Sabbagh, M., Salloway, S., Sampaio, C., Sims, J. R., Sperling, B., Sperling, R., Welsh-Bohmer, K. A., Touchon, J., Vellas, B., & Aisen, P. (2019). Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. The journal of prevention of Alzheimer's disease, 6(3), 164-168. https://doi.org/10.14283/jpad.2019.12

@article{adc4dca5ffc54eefacf102a2889f566a,

title = "Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force",

abstract = "Combination therapy is expected to play an important role for the treatment of Alzheimer's disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer's Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.",

keywords = "Alzheimer{\textquoteright}s disease, amyloid, tau, therapeutics, trial design",

author = "S. Gauthier and J. Alam and H. Fillit and T. Iwatsubo and H. Liu-Seifert and M. Sabbagh and S. Salloway and C. Sampaio and Sims, {J. R.} and B. Sperling and R. Sperling and Welsh-Bohmer, {K. A.} and J. Touchon and B. Vellas and P. Aisen",

year = "2019",

doi = "10.14283/jpad.2019.12",

language = "English",

volume = "6",

pages = "164--168",

journal = "The journal of prevention of Alzheimer's disease",

issn = "2426-0266",

publisher = "Springer International Publishing AG",

number = "3",

}

Gauthier, S, Alam, J, Fillit, H, Iwatsubo, T, Liu-Seifert, H, Sabbagh, M, Salloway, S, Sampaio, C, Sims, JR, Sperling, B, Sperling, R, Welsh-Bohmer, KA, Touchon, J, Vellas, B & Aisen, P 2019, 'Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force', The journal of prevention of Alzheimer's disease, vol. 6, no. 3, pp. 164-168. https://doi.org/10.14283/jpad.2019.12

TY - JOUR

T1 - Combination Therapy for Alzheimer's Disease

T2 - Perspectives of the EU/US CTAD Task Force

AU - Gauthier, S.

AU - Alam, J.

AU - Fillit, H.

AU - Iwatsubo, T.

AU - Liu-Seifert, H.

AU - Sabbagh, M.

AU - Salloway, S.

AU - Sampaio, C.

AU - Sims, J. R.

AU - Sperling, B.

AU - Sperling, R.

AU - Welsh-Bohmer, K. A.

AU - Touchon, J.

AU - Vellas, B.

AU - Aisen, P.

PY - 2019

Y1 - 2019

N2 - Combination therapy is expected to play an important role for the treatment of Alzheimer's disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer's Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.

AB - Combination therapy is expected to play an important role for the treatment of Alzheimer's disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer's Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.

KW - Alzheimer’s disease

KW - amyloid

KW - tau

KW - therapeutics

KW - trial design

UR - http://www.scopus.com/inward/record.url?scp=85072857268&partnerID=8YFLogxK

U2 - 10.14283/jpad.2019.12

DO - 10.14283/jpad.2019.12

M3 - Article

C2 - 31062826

AN - SCOPUS:85072857268

SN - 2426-0266

VL - 6

SP - 164

EP - 168

JO - The journal of prevention of Alzheimer's disease

JF - The journal of prevention of Alzheimer's disease

IS - 3

ER -

Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force

Abstract

Keywords

Access to Document

Fingerprint

Cite this